COMy 2023 | The importance of treating patients with smoldering myeloma at high risk of progression to myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the importance of treating smoldering multiple myeloma (SMM) in patients at a high risk of progression to multiple myeloma, and further highlights baseline characteristics of patients with high-risk SMM. Dr Mateos comments on the use of lenalidomide monotherapy or lenalidomide–dexamethasone combination therapy as a starting point to reduce progression in this group. To conclude, Dr Mateos highlights clinical trials evaluating the potential role of monoclonal antibodies in SMM and calls for further clinical research to understand the mechanisms underlying disease progression. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
